Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study

Akito Miyazaki, Kinnosuke Matsumoto, Motohiro Tamiya, Kiyohide Komuta, Kensuke Kanaoka, Tomoki Kuge, Takayuki Shiroyama, Akihiro Tsukaguchi, Akihiro Tamiya, Keijiro Yamauchi, Hidekazu Suzuki, Yasuhiro Mihashi, Masahide Mori, Koki Moritomo, Yuhei Kinehara, Midori Yoneda, Osamu Morimura, Kouji Azuma, Satoshi Tanaka, Toshie Niki, Akio Osa, Yoshito Takeda, Atsushi Kumanogoh

Open source

DOI: 10.1016/j.jtocrr.2026.100953
Published: 2026-04
Container: JTO Clinical and Research Reports
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2026.100953,
  title = {Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1\% to 49\%: A Retrospective Multicenter Study},
  author = {Akito Miyazaki and Kinnosuke Matsumoto and Motohiro Tamiya and Kiyohide Komuta and Kensuke Kanaoka and Tomoki Kuge and Takayuki Shiroyama and Akihiro Tsukaguchi and Akihiro Tamiya and Keijiro Yamauchi and Hidekazu Suzuki and Yasuhiro Mihashi and Masahide Mori and Koki Moritomo and Yuhei Kinehara and Midori Yoneda and Osamu Morimura and Kouji Azuma and Satoshi Tanaka and Toshie Niki and Akio Osa and Yoshito Takeda and Atsushi Kumanogoh},
  year = {2026},
  journal = {JTO Clinical and Research Reports},
  doi = {10.1016/j.jtocrr.2026.100953},
  url = {https://doi.org/10.1016/j.jtocrr.2026.100953}
}

RIS

TY  - JOUR
TI  - Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study
AU  - Akito Miyazaki
AU  - Kinnosuke Matsumoto
AU  - Motohiro Tamiya
AU  - Kiyohide Komuta
AU  - Kensuke Kanaoka
AU  - Tomoki Kuge
AU  - Takayuki Shiroyama
AU  - Akihiro Tsukaguchi
AU  - Akihiro Tamiya
AU  - Keijiro Yamauchi
AU  - Hidekazu Suzuki
AU  - Yasuhiro Mihashi
AU  - Masahide Mori
AU  - Koki Moritomo
AU  - Yuhei Kinehara
AU  - Midori Yoneda
AU  - Osamu Morimura
AU  - Kouji Azuma
AU  - Satoshi Tanaka
AU  - Toshie Niki
AU  - Akio Osa
AU  - Yoshito Takeda
AU  - Atsushi Kumanogoh
PY  - 2026
JO  - JTO Clinical and Research Reports
DO  - 10.1016/j.jtocrr.2026.100953
UR  - https://doi.org/10.1016/j.jtocrr.2026.100953
ER  -

APA

Miyazaki, A., Matsumoto, K., Tamiya, M., Komuta, K., Kanaoka, K., Kuge, T., Shiroyama, T., Tsukaguchi, A., Tamiya, A., Yamauchi, K., Suzuki, H., Mihashi, Y., Mori, M., Moritomo, K., Kinehara, Y., Yoneda, M., Morimura, O., Azuma, K., Tanaka, S., Niki, T., Osa, A., Takeda, Y., & Kumanogoh, A. (2026). Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study. JTO Clinical and Research Reports. https://doi.org/10.1016/j.jtocrr.2026.100953

Source records

crossref · retrieved 2026-09-27T05:58:51.266Z